← All Inhibikase Therapeutics, INC filings

Inhibikase Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
IKT
Inhibikase Therapeutics, INC
10-K: Inhibikase Therapeutics Advances PAH Drug to Phase 3 Amidst Rising Losses
Inhibikase Therapeutics initiated a global Phase 3 clinical study for its lead product candidate, IKT-001 for Pulmonary Arterial Hypertension, while reporting increased net losses and significant capital raises in 2025.
NASDAQ
IKT
Inhibikase Therapeutics, INC
10-K/A: Inhibikase Therapeutics Files Amendment No. 1 to Form 10-K/A, Updating Executive and Director Information
Inhibikase Therapeutics files an amendment to its annual report to include previously omitted information regarding directors, executive officers, corporate governance, executive compensation, and related matters.
NASDAQ
IKT
Inhibikase Therapeutics, INC
10-K: Inhibikase Therapeutics Pauses Parkinson's Program, Focuses on PAH Treatment After $110M Raise
Inhibikase Therapeutics shifts strategic focus to its IKT-001 program for Pulmonary Arterial Hypertension (PAH) after pausing development of its Parkinson's disease treatment, supported by recent $110 million private placement.
NASDAQ
IKT
Inhibikase Therapeutics, INC
10-K: Inhibikase Therapeutics Outlines Ethical Standards and Provides Business Update
Inhibikase Therapeutics releases its Code of Business Conduct and Ethics while also providing an update on clinical trials and financial status.